Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
Public ClinicalTrials.gov record NCT03221842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a double-blind, randomized-withdrawal, placebo-controlled study in kidney transplant patients with AMR to evaluate the efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care (IVIG).
Study identification
- NCT ID
- NCT03221842
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2017 (Actual)
- Primary completion
- Jan 20, 2021 (Actual)
- Completion
- Jan 20, 2021 (Actual)
- Last update posted
- Jul 29, 2022
2017 – 2021
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Hospital (at Birmingham) | Birmingham | Alabama | 35233 | — |
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| California Pacific | San Francisco | California | 94115 | — |
| Yale New Haven Hospital | New Haven | Connecticut | 06520 | — |
| University of Illinois Chicago | Chicago | Illinois | 60612 | — |
| Brigham & Women's | Boston | Massachusetts | 02115 | — |
| Mayo Clinic (Rochester) | Rochester | Minnesota | 55905 | — |
| St. Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| NYU | New York | New York | 10016 | — |
| Columbia University | New York | New York | 10032 | — |
| Vanderbilt University | Nashville | Tennessee | 37232 | — |
| Houston Methodist | Houston | Texas | 77030 | — |
| University of Wisconsin | Madison | Wisconsin | 53705-2281 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03221842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2022 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03221842 live on ClinicalTrials.gov.